Literature DB >> 21795597

CD8- dendritic cells and macrophages cross-present poly(D,L-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo.

Christopher Schliehe1, Chiara Redaelli, Sabrina Engelhardt, Michael Fehlings, Marc Mueller, Nico van Rooijen, Marc Thiry, Kai Hildner, Horst Weller, Marcus Groettrup.   

Abstract

The analysis of cell types involved in cross-priming of particulate Ag is essential to understand and improve immunotherapies using microparticles. In this study, we show that murine splenic dendritic cells (DCs) as well as macrophages (MΦs) are able to efficiently endocytose poly(D,L-lactate-co-glycolate) acid (PLGA) microspheres (MS) and to cross-present encapsulated Ags in the context of MHC class I molecules in vitro. A comparison of purified CD8(+) and CD8(-) DCs indicated that both DC subtypes are able to present OVA-derived epitopes on MHC class I and II in vitro. To determine the contribution of DCs and MΦs to cross-priming of PLGA MS in vivo, DCs were depleted in transgenic CD11c-DTR mice, and MΦs were depleted by clodronate liposomes in wild-type mice before immunizing mice with OVA-encapsulated MS. Our results show that the depletion of DCs or MΦs alone only led to minor differences in the OVA-specific immune responses. However, simultaneous depletion of DCs and MΦs caused a strong reduction of primed effector cells, indicating a redundancy of both cell populations for the priming of PLGA MS-encapsulated Ag. Finally, we analyzed PLGA MS trafficking to draining lymph nodes after s.c. injection. It was evident that fluorescent particles accumulated within draining lymph nodes over time. Further analysis of PLGA MS-positive lymphatic cells revealed that mainly CD8(-) DCs and MΦs contained MS. Moreover, immune responses in BATF3 knockout mice lacking CD8(+) DCs were normal. The results presented in this work strongly suggest that in vivo cross-priming of PLGA MS-encapsulated Ag is performed by CD8(-) DCs and MΦs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795597     DOI: 10.4049/jimmunol.1002084

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.

Authors:  Shailendra B Tallapaka; Bala V K Karuturi; Pravin Yeapuri; Stephen M Curran; Yogesh A Sonawane; Joy A Phillips; D David Smith; Sam D Sanderson; Joseph A Vetro
Journal:  Int J Pharm       Date:  2019-05-08       Impact factor: 5.875

2.  Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8+ T Cells in a Diameter-Dependent Manner.

Authors:  Bala V K Karuturi; Shailendra B Tallapaka; Pravin Yeapuri; Stephen M Curran; Sam D Sanderson; Joseph A Vetro
Journal:  Mol Pharm       Date:  2017-04-03       Impact factor: 4.939

Review 3.  Engineering nano- and microparticles to tune immunity.

Authors:  James J Moon; Bonnie Huang; Darrell J Irvine
Journal:  Adv Mater       Date:  2012-05-29       Impact factor: 30.849

Review 4.  Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.

Authors:  Dixita Ishani Viswanath; Hsuan-Chen Liu; David P Huston; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Biomaterials       Date:  2021-11-30       Impact factor: 12.479

5.  Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses.

Authors:  Yaoying Wu; Hanning Wen; Zachary J Bernstein; Kelly M Hainline; Tykia S Blakney; Kendra L Congdon; David J Snyder; John H Sampson; Luis Sanchez-Perez; Joel H Collier
Journal:  Sci Adv       Date:  2022-07-20       Impact factor: 14.957

6.  Induction of Potent Antigen-specific Cytotoxic T Cell Response by PLGA-nanoparticles Containing Antigen and TLR Agonist.

Authors:  Young-Ran Lee; Young-Hee Lee; Ki-Hyang Kim; Sun-A Im; Chong-Kil Lee
Journal:  Immune Netw       Date:  2013-02-28       Impact factor: 6.303

7.  Responses of macrophages against Salmonella infection compared with phagocytosis.

Authors:  Maozhi Hu; Yun Yang; Chuang Meng; Zhiming Pan; Xinan Jiao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-08-16       Impact factor: 2.416

8.  Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo.

Authors:  Peng Wang; Shuyun Dong; Peng Zhao; Xiao He; Mingnan Chen
Journal:  Biomaterials       Date:  2018-08-06       Impact factor: 12.479

9.  An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination.

Authors:  Basavaraj Binjawadagi; Varun Dwivedi; Cordelia Manickam; Kang Ouyang; Jordi B Torrelles; Gourapura J Renukaradhya
Journal:  Int J Nanomedicine       Date:  2014-03-24

10.  Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs.

Authors:  Basavaraj Binjawadagi; Varun Dwivedi; Cordelia Manickam; Kang Ouyang; Yun Wu; Ly James Lee; Jordi B Torrelles; Gourapura J Renukaradhya
Journal:  Int J Nanomedicine       Date:  2014-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.